Getting Mounjaro in Leeds: what to expect, step by step

Step 1, Check whether you meet the clinical starting point

Before anything else, it helps to understand the eligibility picture. The Mounjaro licence covers adults with a BMI of 30 or above, or those with a BMI of 27 or above who have at least one condition linked to excess weight, high blood pressure, type 2 diabetes, high cholesterol, obstructive sleep apnoea and cardiovascular disease are the most common examples. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI alone does not guarantee a prescription; a prescriber looks at the full picture, including any contraindications, your current medicines, and whether weight-loss treatment is appropriate for you right now.

A quick way to orient yourself before any consultation: use the NHS BMI calculator to confirm your starting number. It takes under a minute and gives you one useful data point before speaking to a clinician. That's worth doing first.

People who are pregnant, breastfeeding, or trying to conceive should not take Mounjaro. It is not licensed for anyone under 18. If you have a history of medullary thyroid cancer or certain pancreatic conditions, these will need to be discussed with a prescriber before treatment is considered.

Step 2, Understand what the NHS route in Leeds actually offers (and when it opens up)

Leeds sits within the NHS West Yorkshire Integrated Care Board, which follows NHS England's phased rollout of tirzepatide in primary care. NICE's recommendation (TA1026) sets strict NHS eligibility: currently, the NHS route requires a BMI of 40 or above plus four or more of the five qualifying conditions, high blood pressure, dyslipidaemia, sleep apnoea, cardiovascular disease, and type 2 diabetes. A second cohort covering BMI 35–39.9 with four or more conditions became eligible in June 2026. GP participation in the new contract is optional, so availability varies by practice even for those who qualify.

NHS waiting lists for specialist weight management services remain long across West Yorkshire, as they do nationally. Meeting the criteria does not mean immediate access. For Leeds residents who fall outside the current NHS thresholds, or who do not want to wait, a private prescription through a regulated pharmacy is the legal alternative, you can find out more about what that involves on the weight loss treatment overview page.

Step 3, Getting a private prescription safely, wherever you are in Leeds

A private prescription for Mounjaro in Leeds does not require a face-to-face appointment at a clinic in the city. A GPhC-registered online pharmacy can conduct the consultation, issue the prescription, and dispatch the medication, all legally and with the same clinical rigour as an in-person service, provided the pharmacy follows MHRA and GPhC standards.

The key thing to verify is registration. Any online pharmacy dispensing prescription medicines in the UK must appear on the GPhC pharmacy register. Look up the pharmacy by name or registration number before handing over any medical information. Red flags include sellers who offer Mounjaro without asking for a medical consultation, those advertising on social media with no verifiable registration, and prices dramatically below the market range. The MHRA has warned that counterfeit weight-loss pens have caused serious harm, and fake tirzepatide pens have been seized in England as recently as 2025.

At nume, every consultation is reviewed the same day by a GPhC-registered Independent Prescriber, a real clinician reads your answers, not a script. If you're curious about what tirzepatide is and how it works before starting a consultation, the tirzepatide overview page covers the mechanism and trial evidence in plain language.

Side effects Leeds patients ask about most

Nausea is the most commonly reported side effect, particularly in the first few weeks after starting or after a dose increase. Vomiting, loose stools, constipation, reflux and fatigue also appear frequently in trial data and in real-world use. Most gastrointestinal symptoms are at their most noticeable early on and ease as the body adjusts, though this varies from person to person.

Some less obvious effects come up regularly in questions our prescribers receive. If you've seen queries about Mounjaro and connective tissue conditions, or wondered about changes to the menstrual cycle on tirzepatide, these are genuinely asked questions, and answering them properly requires looking at what the evidence does and does not show. On safety, one point worth knowing: the MHRA issued a Drug Safety Update in January 2026 specifically about GLP-1 medicines and acute pancreatitis. Severe stomach pain spreading towards the back, with or without vomiting, warrants urgent medical attention. Report any suspected side effects through the MHRA Yellow Card scheme. Mounjaro also carries a Black Triangle (▼) designation, meaning it is under additional monitoring, that's standard for newer medicines, not a cause for alarm, but it reinforces why clinical oversight matters throughout treatment.

Women taking an oral contraceptive pill should discuss this with their prescriber. Absorption of oral medicines can be affected during the early weeks of tirzepatide treatment and after each dose increase, a backup contraceptive method may be advisable during those windows. Transdermal HRT patches and gels are generally preferred over oral HRT for the same reason; your prescriber can advise. If you have noticed unexpected nosebleeds and are wondering whether Mounjaro could be responsible, it is a question worth raising with your prescriber, and our dedicated page on Mounjaro and nosebleeds looks at what the evidence currently suggests. More on the Mounjaro consultation and what it covers is on the how to get Mounjaro page, and the FAQs page covers common practical questions about treatment.